Research Analysts Offer Predictions for WST Q1 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Stock analysts at Zacks Research reduced their Q1 2025 EPS estimates for West Pharmaceutical Services in a research report issued on Thursday, March 6th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $1.24 for the quarter, down from their previous forecast of $1.62. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q2 2025 earnings at $1.44 EPS, Q3 2025 earnings at $1.65 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at $6.19 EPS, Q1 2026 earnings at $1.43 EPS, Q2 2026 earnings at $1.82 EPS, Q3 2026 earnings at $1.95 EPS, Q4 2026 earnings at $2.02 EPS and FY2026 earnings at $7.23 EPS.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.07. The business had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%.

Several other research firms have also recently issued reports on WST. UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and increased their price objective for the company from $350.00 to $390.00 in a report on Thursday, December 12th. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Bank of America increased their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research note on Friday, February 14th. Finally, Citigroup initiated coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $344.00.

West Pharmaceutical Services Trading Up 2.5 %

West Pharmaceutical Services stock opened at $231.76 on Monday. The firm has a 50 day simple moving average of $291.41 and a 200-day simple moving average of $304.83. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The stock has a market capitalization of $16.76 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services has a 12-month low of $197.01 and a 12-month high of $400.88.

Institutional Investors Weigh In On West Pharmaceutical Services

Several hedge funds have recently made changes to their positions in WST. Principal Financial Group Inc. lifted its position in shares of West Pharmaceutical Services by 2.3% in the 3rd quarter. Principal Financial Group Inc. now owns 91,756 shares of the medical instruments supplier’s stock valued at $27,541,000 after acquiring an additional 2,037 shares in the last quarter. CWA Asset Management Group LLC purchased a new stake in shares of West Pharmaceutical Services in the 3rd quarter valued at approximately $213,000. SpiderRock Advisors LLC lifted its position in shares of West Pharmaceutical Services by 26.2% in the 3rd quarter. SpiderRock Advisors LLC now owns 5,589 shares of the medical instruments supplier’s stock valued at $1,678,000 after acquiring an additional 1,160 shares in the last quarter. Verdence Capital Advisors LLC lifted its position in shares of West Pharmaceutical Services by 86.4% in the 3rd quarter. Verdence Capital Advisors LLC now owns 2,209 shares of the medical instruments supplier’s stock valued at $663,000 after acquiring an additional 1,024 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of West Pharmaceutical Services by 10.1% in the 3rd quarter. Assetmark Inc. now owns 6,533 shares of the medical instruments supplier’s stock valued at $1,961,000 after acquiring an additional 601 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be given a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 annualized dividend and a dividend yield of 0.36%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.56%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.